Long-Term Outcomes in Aortic Stenosis: Mortality Analysis in a Selected Patient Group.

Aortic stenosis (AS) is a prevalent acquired heart valve disease with increasing incidence, particularly among older adults. Gender-specific differences in AS presentation, comorbidities, and outcomes remain underexplored, necessitating further investigation to optimize personalized treatment strategies. To evaluate the clinical and demographic characteristics, comorbidities, and survival outcomes of patients with AS, stratified by gender and aortic valve morphology. A retrospective analysis of 145,454 echocardiographic examinations (2009-2018) at the Federal State Budgetary Institution "V.A. Almazov National Medical Research Centre" identified 84,851 patients meeting the inclusion criteria (Vmax ≥ 2.0 m/s, age ≥ 18 years). Patients were stratified by gender and valve morphology (bicuspid aortic valve [BAV] vs. tricuspid aortic valve [TAV]). Survival was assessed in 475 pts with AS over a 16-year period (2009-2025) using Kaplan-Meier analysis. Statistical comparisons utilized STATISTICA v. 10.0, with -values derived from P-tests. Of the cohort, 4998 men and 6322 women had AS. Men with AS were older (median 64 vs. 57 years, < 0.0001) and had higher systolic blood pressure (140 vs. 130 mmHg, < 0.0001) than men without AS. Women with AS were also older (median 70 vs. 58 years, < 0.0001) with higher systolic (140 vs. 130 mmHg, < 0.0001) and diastolic blood pressure (80 vs. 80 mmHg, < 0.0001). Men with AS had higher rates of hyperlipidemia (HLP) (26.3% vs. 10.3%, < 0.0001), while women with AS had increased coronary artery disease (CAD) (35.7% vs. 26.4%, < 0.0001), diabetes mellitus (DM) (13.4% vs. 10.2%, < 0.0001), and obesity (10.9% vs. 10.2%, = 0.06). Chronic heart failure (CHF) was more frequently reported in patients with AS, regardless of gender, compared to patients without AS (in men 53.4% vs. 41.8%, < 0.0001; in women 54.5% vs. 37.5%, < 0.0001). BAV was associated with higher AS prevalence (54.5% in men, 66.4% in women). Survival analysis revealed higher mortality. Over the 16-year follow-up period, the mortality rate was 21.7%. Mortality in a representative AS cohort reached 21.7%, underscoring the progressive nature of the disease and its long-term impact. Survival was negatively affected by age over 68.5 years, as well as the presence of aortic regurgitation (AR), increased peak aortic jet velocity, and enlarged maximum aortic diameter. Aortic valve replacement demonstrates an insignificant effect on patient survival rates. Beta-blocker therapy in patients with varying degrees of aortic AS severity has not only demonstrated its safety but has also shown a positive effect on reducing mortality (improving survival). In contrast, the combination of angiotensin II receptor blockers (ARBs) with calcium channel blockers (CCBs) is quite dangerous for patients with AS and reduces their survival. Aortic valve replacement demonstrates an insignificant effect on patient survival rates. In contrast, the absence of fibrinolytic therapy and anticoagulant treatment is associated with an improved prognosis. Conversely, the administration of antiarrhythmic agents and statins is correlated with enhanced survival outcomes, potentially attributable to their influence on coexisting comorbidities. Further research is required to delineate their precise mechanisms and contributions. These results emphasize the importance of early identification, comprehensive risk assessment, and individualized management strategies in improving outcomes for patients with AS.